Association between serum folate levels and schizophrenia based on sex.
folate
homocysteine
pyridoxal
schizophrenia
vitamin B6
Journal
Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
04
03
2020
revised:
17
04
2020
accepted:
10
05
2020
pubmed:
24
5
2020
medline:
16
10
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
Sex differences in serum folate concentrations are well known, but no studies have investigated the association between serum folate levels and schizophrenia based on sex. With this study in a Japanese population, we examined the difference in serum folate levels between patients with schizophrenia and non-psychiatric controls stratified by sex. The relations among serum folate levels, plasma total homocysteine (tHcy), and serum vitamin B6 (pyridoxal) levels were also examined using data from our previous studies. The serum folate concentrations of 482 patients diagnosed with schizophrenia and 1350 non-psychiatric control subjects were measured. We conducted an analysis of covariance to examine the differences in serum folate levels between the two groups based on sex. Spearman's rank correlation was used to evaluate the relations among folate, tHcy, and vitamin B6 levels. In the control group, serum folate concentrations were higher in women than in men. Lower levels of serum folate were observed in both male and female patients with schizophrenia. An inverse correlation between serum folate and plasma tHcy and a weak positive correlation between serum folate and vitamin B6 were observed in the combined cohort. Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels.
Substances chimiques
Homocysteine
0LVT1QZ0BA
Vitamin B 6
8059-24-3
Folic Acid
935E97BOY8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
466-471Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18dk0307076h0001
Organisme : Japan Society for the Promotion of Science
ID : 18H02751
Organisme : Japan Society for the Promotion of Science
ID : 19K08075
Organisme : the Japan Agency for Medical Research and Development
Informations de copyright
© 2020 The Authors Psychiatry and Clinical Neurosciences © 2020 Japanese Society of Psychiatry and Neurology.
Références
Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv. Rev. Psychiatry 2007; 15: 146-160.
Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia: Current challenges and future directions. Trends Mol. Med. 2009; 15: 562-570.
Kinoshita M, Numata S, Tajima A et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med. 2013; 15: 95-101.
Nishi A, Numata S, Tajima A et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr. Bull. 2014; 40: 1154-1163.
Arai M, Miyashita M, Kobori A, Toriumi K, Horiuchi Y, Itokawa M. Carbonyl stress and schizophrenia. Psychiatry Clin. Neurosci. 2014; 68: 655-665.
Kinoshita M, Numata S, Tajima A et al. Cumulative effect of the plasma total homocysteine-related genetic variants on schizophrenia risk. Psychiatry Res. 2016; 246: 833-837.
Kinoshita M, Numata S, Tajima A et al. Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia. Int. J. Mol. Sci. 2017; 18: 632.
Itokawa M, Miyashita M, Arai M et al. Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin. Neurosci. 2018; 72: 35-44.
Tomioka Y, Numata S, Kinoshita M et al. Decreased serum pyridoxal levels in schizophrenia: Meta-analysis and Mendelian randomization analysis. J. Psychiatry Neurosci. 2018; 43: 194-200.
Kuehner JN, Bruggeman EC, Wen Z, Yao B. Epigenetic regulations in neuropsychiatric disorders. Front. Genet. 2019; 10: 268.
McGarel C, Pentieva K, Strain JJ, McNulty H. Emerging roles for folate and related B-vitamins in brain health across the lifecycle. Proc. Nutr. Soc. 2015; 74: 46-55.
Herrán A, García-Unzueta MT, Amado JA, López-Cordovilla JJ, Díez-Manrique JF, Vázquez-Barquero JL. Folate levels in psychiatric outpatients. Psychiatry Clin. Neurosci. 1999; 53: 531-533.
Goff DC, Bottiglieri T, Arning E et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am. J. Psychiatry 2004; 161: 1705-1708.
Lee YS, Han DH, Jeon CM et al. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport 2006; 17: 743-746.
Petronijević ND, Radonjić NV, Ivković MD et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 1921-1926.
Kale A, Naphade N, Sapkale S et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res. 2010; 175: 47-53.
Kim TH, Moon SW. Serum homocysteine and folate levels in Korean schizophrenic patients. Psychiatry Investig. 2011; 8: 134-140.
Song X, Fan X, Li X et al. Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia. Schizophr. Res. 2014; 159: 51-55.
Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A. Elevated homocysteine level in first-episode schizophrenia patients: The relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab. Brain Dis. 2014; 29: 661-670.
Takano Y, Ozeki Y, Sekine M et al. Multi-regression analysis revealed a relationship between l-serine and methionine, a component of one-carbon metabolism, in the normal control but not in the schizophrenia. Ann. Gen. Psychiatry 2016; 15: 23.
Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: A possible association. Biol. Psychiatry 1998; 44: 141-143.
Ozcan O, Ipçioğlu OM, Gültepe M, Başoğglu C. Altered red cell membrane compositions related to functional vitamin B(12) deficiency manifested by elevated urine methylmalonic acid concentrations in patients with schizophrenia. Ann. Clin. Biochem. 2008; 45: 44-49.
Eren E, Yeğin A, Yilmaz N, Herken H. Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clin. Lab. 2010; 56: 513-518.
García-Miss Mdel R, Pérez-Mutul J, López-Canul B et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa [sic] levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J. Psychiatr. Res. 2010; 44: 441-446.
Bouaziz N, Ayedi I, Sidhom O et al. Plasma homocysteine in schizophrenia: Determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res. 2010; 179: 24-29.
Ayesa-Arriola R, Pérez-Iglesias R, Rodríguez-Sánchez JM et al. Homocysteine and cognition in first-episode psychosis patients. Eur. Arch. Psychiatry Clin. Neurosci. 2012; 262: 557-564.
Cao B, Wang DF, Xu MY et al. Lower folate levels in schizophrenia: A meta-analysis. Psychiatry Res. 2016; 245: 1-7.
Wang D, Zhai JX, Liu DW. Serum folate levels in schizophrenia: A meta-analysis. Psychiatry Res. 2016; 235: 83-89.
Cohen E, Margalit I, Shochat T, Goldberg E, Krause I. Gender differences in homocysteine concentrations, a population-based cross-sectional study. Nutr. Metab. Cardiovasc. Dis. 2019; 29: 9-14.
Muntjewerff JW, van der Put N, Eskes T et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: Low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res. 2003; 121: 1-9.
Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 1289-1296.
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: A systematic review. J. Psychiatr. Res. 2013; 47: 197-207.
Kim EJ, Lim SY, Lee HJ et al. Low dietary intake of n-3 fatty acids, niacin, folate, and vitamin C in Korean patients with schizophrenia and the development of dietary guidelines for schizophrenia. Nutr. Res. 2017; 45: 10-18.
Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: A systematic review and meta-analysis. Psychopharmacology (Berl.) 2018; 235: 2303-2314.
Roffman JL, Petruzzi LJ, Tanner AS et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: A randomized controlled trial. Mol. Psychiatry 2018; 23: 316-322.
Wang B, Wu H, Li Y et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: Major effect modifiers. Br. J. Nutr. 2018; 120: 1122-1130.
Bender A, Hagan KE, Kingston N. The association of folate and depression: A meta-analysis. J. Psychiatr. Res. 2017; 95: 9-18.
Hsieh YC, Chou LS, Lin CH, Wu HC, Li DJ, Tseng PT. Serum folate levels in bipolar disorder: A systematic review and meta-analysis. BMC Psychiatry 2019; 19: 305.